Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.68 |
| ▸ | TK1 | P04183 | 5/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TK2 | O00142 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774263 | 1.00 | RNASE1 (0.68) | RNASE1TK1SLC6A2LMNATSHR | |
| SCHEMBL14681227 | 1.00 | RNASE1 (0.68) | RNASE1TK1SLC6A2LMNATSHR | |
| SCHEMBL16287348 | 1.00 | RNASE1 (0.68) | RNASE1TK1SLC6A2LMNATSHR | |
| SCHEMBL3337696 | 0.92 | RNASE1 (0.71) | RNASE1TK1SLC6A2LMNATSHR | |
| SCHEMBL19407973 | 0.92 | RNASE1 (0.71) | RNASE1TK1SLC6A2LMNATSHR | |
| SCHEMBL13901238 | 0.92 | RNASE1 (0.71) | RNASE1TK1SLC6A2LMNAALB | |
| SCHEMBL16349867 | 0.92 | RNASE1 (0.71) | RNASE1TK1SLC6A2LMNAALB | |
| SCHEMBL5180425 | 0.90 | ABCG2 (0.59) | RNASE1TK1 | |
| SCHEMBL4099261 | 0.89 | TK1 (0.61) | RNASE1TK1SLC6A2LMNATSHR | |
| SCHEMBL265601 | 0.89 | RNASE1 (0.74) | RNASE1TK1LMNATSHRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | NISSAN CHEMICAL CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
| EP-3378869-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Nissan Chemical Corporation (JP) | 2018-09-26 | — | — | EP | disclosed |
| US-5646260-A | PHOSPHORYLATED OLIGONUCLEOTIDES | LETSINGER ROBERT L (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997019092-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
| EP-0678096-B1 | SYNTHESIS OF DIMMER BLOCKS AND THEIR USE IN ASSEMBLING OLIGONUCLEOTIDES | HYBRIDON INC (US) | 1997-03-19 | — | — | EP | disclosed |
| US-5476925-A | Antisense agents | NORTHWESTERN UNIVERSITY (US) | 1995-12-19 | — | — | US | disclosed |
| US-5218102-A | Easily synthesized, hybridize well with target sequences | IMPROBIO (BE) | 1993-06-08 | — | — | US | disclosed |
| US-4973679-A | Process for oligonucleo tide synthesis using phosphormidite intermediates | UNIVERSITY PATENTS, INC. (US) | 1990-11-27 | — | — | US | disclosed |
| US-4668777-A | POLYNUCLEOTIDE INTERMEDIATES | UNIVERSITY PATENTS, INC. (US) | 1987-05-26 | — | — | US | disclosed |
| EP-0061746-B1 | PHOSPHORAMIDITE COMPOUNDS AND THEIR USE IN PRODUCING OLIGONUCLEOTIDES | UNIVERSITY PATENTS, INC. (US) | 1985-03-20 | — | — | EP | disclosed |
| US-4415732-A | STORAGE-STABLE NUCLEOSIDES; POLYNUCLEOTIDE SYNTHESIS | UNIVERSITY PATENTS, INC. (US) | 1983-11-15 | — | — | US | disclosed |
| EP-0061746-A1 | Phosphoramidite compounds and their use in producing oligonucleotides | UNIVERSITY PATENTS, INC. (US) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | RNASE1 1089/4885TK1 3864/4885SLC6A2 4756/4885 |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | RNASE1 1089/4885TK1 3864/4885SLC6A2 4756/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | RNASE1 1089/4885TK1 3864/4885SLC6A2 4756/4885 |
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | RNASE1 301/4885TK1 183/4885SLC6A2 3077/4885 |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, OSGEP, PHAX | RNASE1 301/4885TK1 183/4885SLC6A2 3077/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | RNASE1 1089/4885TK1 3864/4885SLC6A2 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.